TrialClinical pharmacology in drug development2026

A multipart phase 1 study of the safety, pharmacodynamics and pharmacokinetics of ALG-055009, a novel thyroid hormone receptor beta (THR-β) agonist for metabolic dysfunction-associated steatohepatitis (MASH), in healthy participants.

Hakim Charfi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.